JPRN-jRCT2011210072进行中（未招募）2 期
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-Severe Atopic Dermatitis
Tanaka Tomoyuki0 个研究点目标入组 350 人开始时间: 2022年3月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 < 75age old（—）
- 性别
- All
入选标准
- •Adults (18 to < 75 years of age) with AD (Atopic dermatitis) as defined by the American Academy of Dermatology Consensus Criteria for 1 year or longer at Baseline.
- •- EASI (Eczema Area and Severity Index) of 12 or higher at the Screening Visit and 16 or higher at Baseline.
- •- IGA (Investigator Global Assessment) of 3 or 4 at Baseline.
- •- AD involvement of 10% or more of body surface area (BSA) at Baseline.
- •- Baseline worst / maximum pruritus NRS of >= 4.
- •- Documented history, within 6 months prior to Baseline, of either inadequate response or inadvisability of topical treatments.
- •- Must have applied a stable dose of topical bland emollient (simple moisturizer, no additives [e.g., urea]) at least twice daily for a minimum of 7 consecutive days before Baseline.
- •- Able to complete patient questionnaires
- •- Able and willing to comply with requested study visits / telephone and procedures.
- •- Able and willing to provide written informed consent.
- •- For patients who decide to join the biopsy sub-study be able and willing to provide skin biopsies.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
排除标准
- •- Treatment within specific time windows before the baseline visit for the management of atopic dermatitis such as topical or systemic corticosteroids, biologic or investigational therapies and/or phototherapy.
- •- Known history of, or suspected, significant current immunosuppression, including history of invasive opportunistic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
- •- Weight < 40 kg or > 150 kg at Baseline.
- •- Treatment with a live (attenuated) immunization within 12 weeks prior to Baseline.
- •- Men and women (of reproductive potential) unwilling to use birth control and women who are pregnant or breastfeeding.
- •- Any malignancies or history of malignancies prior to Baseline (except for non-melanoma skin cancer that has been excised and cured for more than 3 years prior to Baseline; in situ cervical carcinoma that has been excised and cured).
- •- Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C at the screening visit.
- •-Severe concomitant illness that would in the Investigator's opinion inhibit the patient's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease.
- •-In the Investigator's opinion, any additional clinically significant laboratory results from the clinical chemistry, haematology or urinalysis tests at the Screening Visit.
- •-Concurrent participation in any other clinical study, including non-interventional studies.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究者
相似试验
未知
2 期
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of S-297995 for the Treatment of Opioid-induced Constipation (OIC) in Cancer PatientsJPRN-jRCT2080221471SHIONOGI & CO., LTD.212
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007MedDRA version: 9.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosussystemic lupus erythematosusEUCTR2007-002566-35-BECB Inc210
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007MedDRA version: 9.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosussystemic lupus erythematosusEUCTR2007-002566-35-LTCB Inc210
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007systemic lupus erythematosusEUCTR2007-002566-35-GBCB Inc210
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007systemic lupus erythematosusEUCTR2007-002566-35-HUCB Inc210